Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease

Gisbert, 2009, Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review, Am J Gastroenterol, 104, 760 Allez, 2010, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects, J Crohn's Colitis, 4, 355, 10.1016/j.crohns.2010.04.004 Ungar, 2017, Addition of a immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab, Pharmacol Ther, 45, 276 Maser, 2006, Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease, Clin Gastroenterol Hepatol, 4, 1248, 10.1016/j.cgh.2006.06.025 Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: The ATLAS study. Gut. 2015. Epub ahead of print. Colombel, 2010, SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492 Roblin, 2017, Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial, Pharmacol Ther, 46, 142 Matsumoto, 2016, Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial, J Crohn's Colitis, 10, 1259, 10.1093/ecco-jcc/jjw152 de Boer, 2018, Thiopurines in inflammatory bowel disease: new findings and perspectives, J Crohn's Colitis, 12, 610, 10.1093/ecco-jcc/jjx181 Toruner, 2008, Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, 134, 929, 10.1053/j.gastro.2008.01.012 Vande Casteele, 2012, Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays, Pharmacol Ther Food, 36, 765 Ben-Horin, 2011, Review article: loss of response to anti-TNF treatments in Crohn's disease, Aliment Pharmacol Ther, 33, 987, 10.1111/j.1365-2036.2011.04612.x Moss, 2015, Optimizing the use of biological therapy in patients with inflammatory bowel disease, Gastroenterol Rep (Oxf), 3, 63, 10.1093/gastro/gou087 Bar-Yoseph, 2018, Early drug and anti-infliximab antibody levels for prediction of primary non-response to infliximab therapy, Pharmacol Ther, 47, 212 Brandse, 2016, Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis, Clin Gastroenterol Hepatol, 14, 251, 10.1016/j.cgh.2015.10.029 Ungar, 2014, The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, Gut, 63, 1258, 10.1136/gutjnl-2013-305259 Brandse, 2017, A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease, Inflamm Bowel Dis, 23, 650, 10.1097/MIB.0000000000001043 Singh, 2014, Early infliximab trough levels are associated with persistent remission in paediatric patients with inflammatory bowel disease, Inflamm Bowel Dis, 20, 1708, 10.1097/MIB.0000000000000137 Baert, 2016, Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial, Gut, 65, 1126, 10.1136/gutjnl-2014-307882 Ding, 2016, Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management, Pharmacol Ther, 43, 30 Cornillie, 2014, Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial, Gut, 63, 1721, 10.1136/gutjnl-2012-304094 Vande Casteele, 2015, The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease, Gut, 64, 1539, 10.1136/gutjnl-2014-307883 Buurman, 2015, Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice, Pharmacol Ther, 42, 529 Steenholdt, 2014, Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial, Am J Gastroenterol, 109, 1055, 10.1038/ajg.2014.106 Strik, 2017, Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease, Pharmacol Ther, 45, 1128 Assche, 2008, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004 Mackey, 2007, cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease, J Paediatr Gastroenterol Nutr, 44, 265, 10.1097/MPG.0b013e31802f6424 Marehbian, 2009, Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease, Am J Gastroenterol, 104, 2524, 10.1038/ajg.2009.322 Lennard, 1987, Thiopurine pharmacogenetics in leukaemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations, Clin Pharmacol Ther, 41, 18, 10.1038/clpt.1987.4 Na, 2016, Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia, Br J Haematol, 174, 550, 10.1111/bjh.14083